RxDoctor Payments DataLook up a doctor →

Ivo Bekavac, MD

Neurology · Waterloo, IANPI 1619920089

Payments from drug & device makers

$9,762in general payments, 2019–2025

Across 580 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$846
  • Novartis$611
  • SK Life Science, Inc.$569
  • Sunovion Pharmaceuticals Inc.$430
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$621%
  • Food & beverage$9,68699%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,762 in reported general payments places this provider in the 80th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$182,520
Medicare patients
544
Services billed
3,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant39$47,706
VimpatLacosamide27$29,892
Aimovig AutoinjectorErenumab-Aooe29$27,756
Glatiramer Acetate14$27,306
GlatopaGlatiramer Acetate15$20,829
Carbidopa-LevodopaCarbidopa/Levodopa586$19,332
AptiomEslicarbazepine Acetate13$18,665
Tegretol XrCarbamazepine17$12,763
LamictalLamotrigine15$12,378
Levetiracetam200$11,673
Emgality PenGalcanezumab-Gnlm16$10,971
Primidone260$8,951
Ajovy SyringeFremanezumab-Vfrm11$7,934
Oxcarbazepine96$7,906
NamzaricMemantine Hcl/Donepezil Hcl12$6,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Namzaric$1,613$54,60251 claims
UCB, Inc.Vimpat$54$29,89227 claims
Sunovion Pharmaceuticals Inc.Aptiom$430$18,66513 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$244$6,16371 claims
PfizerDilantin$1,103$1,82315 claims
Upsher-smith Laboratories LLCTopiramate$16$1,450108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 neurology providers in Iowa.

Other neurology in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →